New drug duo targets persistent 'Mono' virus in adults
NCT ID NCT07369739
Summary
This study is testing whether a combination of two drugs, golidocitinib and selinexor, can help control chronic active Epstein-Barr virus disease (CAEBVD) in adults. The goal is to reduce the amount of virus in the blood and improve disease symptoms. It is for adults aged 18-70 who meet specific health criteria and have been diagnosed with CAEBVD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.